Company overview
Basic information
Company name
ŽALIASIS MEDIS, UAB
Company code
302623853
Registered address
Trakų r. sav., Lentvaris, Geležinkelio g. 57A, LT-25116
Registration date
2011-05-05
Company age: 15 y. 5 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Sawmilling and planing of wood
Ownership form
Private without foreign capital
UAB ŽALIASIS MEDIS
Company code: 302623853
Address: Trakų r. sav., Lentvaris, Geležinkelio g. 57A, LT-25116
Description
This description was generated by artificial intelligence.
ŽALIASIS MEDIS, UAB (company code 302623853) is an operational private limited liability company registered in 2011. It is classified as a private entity within the national private non-financial companies sector and is privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Governance is CEO only, and the company is classified as micro. The business is based in Lentvaris, Traku r. sav., Vilniaus apskr., at Geležinkelio g. 57A. Its main activity is EVRK code C.16.11.00, Sawmilling and planing of wood. Financially, the company has remained small but has seen a weakening performance trend. Revenue decreased from €28.6K in 2023 to €22.7K in 2024 and €16.1K in 2025, with a net loss of €7.4K in 2025 after a loss of €2.1K in 2024 and profit of €4.8K in 2023. Equity declined to €1.9K at the end of 2025, while liabilities increased to €6.8K and total assets stood at €8.8K. The workforce averaged 2 employees in 2023-2025 and 3 employees so far in 2026.
Download a detailed company report
Make confident decisions with all the information about ŽALIASIS MEDIS, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.